Zoetis Inc. Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax
Zoetis Inc. (ZTS) reported Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax of -$58.00 million for the 12-month period ending 2020-12-31, per its 10-K filed 2021-02-16.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax · last filed 2021-02-16
- Zoetis Inc. other comprehensive income (loss), derivatives qualifying as hedges, net of tax for the quarter ending 2020-09-30 was $5.00M.
- Zoetis Inc. other comprehensive income (loss), derivatives qualifying as hedges, net of tax for the quarter ending 2020-06-30 was -$4.00M, a 500.00% decline year-over-year.
- Zoetis Inc. other comprehensive income (loss), derivatives qualifying as hedges, net of tax for the quarter ending 2019-12-31 was $15.00M, a 50.00% increase year-over-year.
- Zoetis Inc. other comprehensive income (loss), derivatives qualifying as hedges, net of tax for the quarter ending 2019-09-30 was -$4.00M.
- Zoetis Inc. other comprehensive income (loss), derivatives qualifying as hedges, net of tax for fiscal 2020 was -$58.00M, a 583.33% decline from fiscal 2019.
- Zoetis Inc. other comprehensive income (loss), derivatives qualifying as hedges, net of tax for fiscal 2019 was $12.00M, a 33.33% increase from fiscal 2018.
- Zoetis Inc. other comprehensive income (loss), derivatives qualifying as hedges, net of tax for fiscal 2018 was $9.00M.
- Zoetis Inc. other comprehensive income (loss), derivatives qualifying as hedges, net of tax for fiscal 2017 was $0.00, a 100.00% decline from fiscal 2016.
| Period end | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax 3 month | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax 6 month | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax 9 month | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax 12 month | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax 12 month as first filed |
|---|---|---|---|---|---|
| 2020-12-31 | -$58.00M 10-K · filed 2021-02-16 | ||||
| 2020-09-30 | $5.00M 10-Q · filed 2020-11-05 | $1.00M derived: sum of 2 quarters · filed 2020-11-05 | |||
| 2020-06-30 | -$4.00M 10-Q · filed 2020-08-06 | ||||
| 2019-12-31 | $15.00M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-16 | $11.00M derived: sum of 2 quarters · filed 2021-02-16 | $12.00M derived: sum of 3 quarters · filed 2021-02-16 | $12.00M 10-K · filed 2021-02-16 | |
| 2019-09-30 | -$4.00M 10-Q · filed 2020-11-05 | -$3.00M derived: sum of 2 quarters · filed 2020-11-05 | -$3.00M 10-Q · filed 2019-11-07 | ||
| 2019-06-30 | $1.00M 10-Q · filed 2020-08-06 | $1.00M 10-Q · filed 2019-08-06 | |||
| 2018-12-31 | $10.00M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-16 | $9.00M derived: sum of 2 quarters · filed 2021-02-16 | $9.00M derived: sum of 3 quarters · filed 2021-02-16 | $9.00M 10-K · filed 2021-02-16 | -$1.00M 10-K · filed 2019-02-14 |
| 2018-09-30 | -$1.00M 10-Q · filed 2019-11-07 | -$1.00M derived: sum of 2 quarters · filed 2019-11-07 | -$1.00M 10-Q · filed 2019-11-07 | ||
| 2018-06-30 | $0.00 10-Q · filed 2019-08-06 | $0.00 10-Q · filed 2019-08-06 | |||
| 2017-12-31 | $11.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-13 | $1.00M derived: sum of 2 quarters · filed 2020-02-13 | $0.00 derived: sum of 3 quarters · filed 2020-02-13 | $0.00 10-K · filed 2020-02-13 | -$11.00M 10-K · filed 2018-02-15 |
| 2017-10-01 | -$10.00M 10-Q · filed 2018-11-01 | -$11.00M derived: sum of 2 quarters · filed 2018-11-01 | -$11.00M 10-Q · filed 2018-11-01 | ||
| 2017-07-02 | -$1.00M 10-Q · filed 2018-08-02 | -$1.00M 10-Q · filed 2018-08-02 | |||
| 2016-12-31 | $12.00M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-14 | $13.00M derived: sum of 2 quarters · filed 2019-02-14 | $10.00M derived: sum of 3 quarters · filed 2019-02-14 | $10.00M 10-K · filed 2019-02-14 | |
| 2016-10-02 | $1.00M 10-Q · filed 2017-11-02 | -$2.00M derived: sum of 2 quarters · filed 2017-11-02 | -$2.00M 10-Q · filed 2017-11-02 | ||
| 2016-07-03 | -$3.00M 10-Q · filed 2017-08-08 | -$3.00M 10-Q · filed 2017-08-08 | |||
| 2015-12-31 | -$2.00M 10-K · filed 2018-02-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |